Comparison of the effect of minoxidil and spironolactone with minoxidil and finasteride in the treatment of Androgenic Alopecia
Phase 3
Recruiting
- Conditions
- Androgenic Alopecia.Androgenic alopecia
- Registration Number
- IRCT20211210053343N1
- Lead Sponsor
- Iran University of Medical Sciences
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Recruiting
- Sex
- Female
- Target Recruitment
- 60
Inclusion Criteria
scalp involvement
aged 15-45 years
satisfaction to participate in the study
ability to follow the patient based on the doctor's diagnosis
normal hormonal tests
Exclusion Criteria
having an underlying disease
history of polycystic ovary syndrome
history of treatment in the last two months for the disease
contraindications to the use of spironolactone or finasteride such as pregnancy and lactation
concomitant use of drugs that may interact with the drugs under study
Study & Design
- Study Type
- interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method
Related Research Topics
Explore scientific publications, clinical data analysis, treatment approaches, and expert-compiled information related to the mechanisms and outcomes of this trial. Click any topic for comprehensive research insights.
What molecular mechanisms underlie the efficacy of spironolactone and finasteride in androgenic alopecia?
How does the combination of minoxidil with spironolactone compare to minoxidil with finasteride in treating female and male pattern hair loss?
What biomarkers are associated with response to minoxidil-spironolactone or minoxidil-finasteride therapy in androgenic alopecia?
What are the adverse event profiles of spironolactone and finasteride when combined with minoxidil for hair loss?
Are there alternative combination therapies to minoxidil-spironolactone or minoxidil-finasteride for androgenic alopecia treatment?